Arthroplasty ComplicationsPhase 4NCT05707234
Virtual Reality Hypnosis in Total Knee Arthroplasty Under Spinal Anesthesia
A Phase 4 study testing VRH and Midazolam sedation in people with Arthroplasty Complications and Knee Osteoarthritis, run by University of Liege at 1 site in Belgium.
Trial summary
For many years, total knee arthroplasty (TKA) has been a common and effective procedure to treat chronic refractory joint pain. Although efforts must be pursued, as general anesthesia remains the main tendency for TKA. Currently, the standard of care to manage procedural anxiety is pharmacological sedation; i.e. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Arthroplasty Complications, Knee Osteoarthritis, Anesthesia Complication
- What is being tested?
- VRH and Midazolam sedation
- Type of treatment
- Pill or oral medicine, Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteBelgium
- Study dates
- 15 Feb 2023to 3 Aug 2023
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients >18 yo and scheduled for elective knee arthroplasty under spinal anesthesia
Who cannot join
- Low auditory and/or visual acuity that precludes the use of the device.
- ASA status > 3
- Head or face wounds precluding use of the device.
- Schizophrenia or dissociative disorder.
- Pregnancy.
- Chronic renal insufficiency or severe hepatic insufficiency.
Show all 12Show fewer
- Non-proficiency in French (Research language).
- Phobia of deep water.
- Chronic pain and/or chronic analgesics consumption.
- Medication affecting the autonomic nervous system.
- Revision surgery.
- Dizziness.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Can we Avoid Intravenous Sedation in Patients Undergoing Knee Surgery Under Spinal Anesthesia? A Prospective Randomized Controlled Study Comparing Virtual Reality Hypnosis to Standard of Care
For many years, total knee arthroplasty (TKA) has been a common and effective procedure to treat chronic refractory joint pain. Although efforts must be pursued, as general anesthesia remains the main tendency for TKA. Currently, the standard of care to manage procedural anxiety is pharmacological sedation; i.e. the intravenous administration of additional anesthetic agents such as propofol or midazolam. However, pharmacological sedation has considerable undesirable side effects. Hence, risks of intraprocedural adverse events including respiratory depression, hemodynamic perturbations, or paradoxical effects such as hostility, aggression, and psychomotor agitation, are increased. The goal of this prospective, single-center, randomized controlled clinical trial is to systematically evaluate the impact of implementing a protocol of virtual reality hypnosis in patients undergoing total knee arthroplasty under spinal anesthesia.
Read the detailed description
For many years, total knee arthroplasty (TKA) has been a common and effective procedure to treat chronic refractory joint pain. With a worldwide aging population, as well as a rising rate of obesity and related osteoarthritis, the utilization of TKA has considerably expanded over time, and this increase is expected to continue. Accordingly, healthcare systems are exploring various strategies to address this growing demand, while ensuring efficiency, cost-effectiveness and safety. Among these approaches, and based on several reports comparing the risks and benefits of general and regional anesthesia, a first attempt has been made to switch from performing TKAs under general to spinal anesthesia. Although efforts must be pursued, as general anesthesia remains the main tendency for TKA, results regarding spinal anesthesia are extremely encouraging. As such, spinal anesthesia has been associated with a decreased rate of complications, including wound infection, blood transfusions or mortality, and with reduced length of surgery and hospital stay.
Yet, while spinal anesthesia prevents procedural pain and ensures immobility of the operative territory, the patient is still awake, conscious of all the noises in the operating room, and can have a high level of intraoperative anxiety. Currently, the standard of care to manage procedural anxiety is pharmacological sedation; i.e. the intravenous administration of additional anesthetic agents such as propofol or midazolam. However, pharmacological sedation has considerable undesirable side effects. Hence, risks of intraprocedural adverse events including respiratory depression, hemodynamic perturbations, or paradoxical effects such as hostility, aggression, and psychomotor agitation, are increased. Moreover, it might lead to longer procedure duration or time to discharge, slower recovery, and postoperative delirium or cognitive dysfunction. In addition to these challenges, it becomes clear that procedural sedation directly impacts consumption of drugs such as opioids, triggering the highlighted risk of addiction.
In this context, new international guidelines for risk mitigation in pharmacological sedation have emerged. Both American and European anesthesia societies recommend particular caution in the use of sedative drugs, especially with benzodiazepines and in patients with obesity or obstructive sleep apnea, which are highly comorbid with knee osteoarthritis. However, only providing less, or even no sedatives at all, is not a valuable solution, as it would negatively impact patient comfort and satisfaction and negatively affect clinical workflow. Therefore, alternative, non-pharmacological interventions that would be able to reduce drug requirements and associated risks while ensuring a similar patient experience are being actively sought.
Among those approaches, there is currently a growing interest towards clinical hypnosis, a one-to-one delivered technique inducing "A state of consciousness involving focused attention and reduced peripheral awareness characterized by an enhanced capacity for response to suggestion". The hypnotic state involves the capacities of absorption (tendency to be fully involved in a mental experience), dissociation (a mental separation from the environment), and suggestibility (tendency to comply with hypnotic suggestions). When combined during surgery with conscious IV sedation and local or regional anesthesia, forming the so-called hypnosedation, clinical hypnosis is associated with improved perioperative safety and comfort as well as better clinical outcomes. More precisely, the use of clinical hypnosis during medical procedures has been shown to reduce pain, emotional distress and anxiety while preserving consciousness, spontaneous breathing, reflexes as well as hemodynamic and metabolic changes, to decrease the time spent in the operating room, and to have a beneficial impact on immediate recovery, characterized by reduced fatigue and postoperative nausea and vomiting (PONV). Furthermore, this technique allows to significantly reduce the administrated doses of IV sedation and the associated costs. Yet, several obstacles limit the use of hypnosedation as a standard of care in the operating/ procedure room: the need for continuous patient-side presence of trained professionals in the room (and the cost related to the mobilization of these professionals), the small number of cases per day one healthcare provider can handle, patient's language proficiency, as well as the heterogeneity of the responses to the hypnotic suggestions of patients themselves.
To overcome those limitations, Oncomfort has created Digital Sedation™ sessions, classified as Software as a Medical Device (SaMD), allowing to deliver clinical hypnosis - together with additional integrative therapeutic approaches - through virtual reality, a technique called Virtual Reality Hypnosis (VRH). Virtual reality (VR) is "a computer-generated simulation of a lifelike environment that can be interacted with in a seemingly real or physical way by a person, by means of responsive hardware such as a visor with screen or gloves with sensors. In the medical field, VR has been used as a non-pharmacological mean to alleviate pain, anxiety, and general discomfort during uncomfortable procedures. VR is thought to work by distracting patients from uncomfortable procedures: by giving the illusion of really going into the artificial world, VR is able to capture patient's attention away from the real environment. Accordingly, VR could strengthen the level of absorption and dissociation induced by clinical hypnosis, especially in low hypnotizable persons. Hence, VRH technology allows to deliver clinical hypnosis - and its related benefits- to a considerably greater number of patients. This automated way of delivering hypnosis responds to most of the limitations of the use of clinical hypnosis mentioned supra (e.g. availability of trained staff, language barrier,…).
To date, the Oncomfort's Digital Sedation™ is used in more than 100 hospitals, and more than 80 000 patients have already beneficiated from this type of VRH in daily clinical practice (e.g. interventional radiology, oncology, surgery,…). In line with its intended use, first studies have demonstrated that Digital Sedation™ reduces both experimental and clinical pain, as well as procedural anxiety. In addition, preliminary results indicate that it might replace midazolam during endoscopic urologic surgery, avoiding the respiratory side effects associated with pharmacological sedation. Over the last year, at the CHU of Liège, Digital Sedation™ has been offered to patients during orthopedic surgeries, demonstrating the feasibility of using VRH during TKAs performed under spinal anesthesia. While results seem to be positive in terms of performance of the procedure and patient satisfaction, the potential beneficial impact of this solution has not been systematically addressed yet. The goal of the present study is to objectify those effects, and in particular, to determine whether VRH can replace - at least in part- the intraoperative administration of midazolam, allowing to avoid its associated side effects while ensuring a similar patient's comfort.
- Conditions
- Arthroplasty Complications, Knee Osteoarthritis, Anesthesia Complication, Hypnotic; Anxiety Disorder, Sedation Complication
- Being tested
- VRH, Midazolam sedation
- Medical subject headings
- Osteoarthritis, Knee, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VRHDevice
The VR headset and headphones will be placed on patients after the spinal anesthesia, once the patient is positioned and the surgical drapes installed. Patients will then undergo a 120-minute Digital Sedation™ program (Aqua+© 120 Version 1.1 or subsequent version, Oncomfort SA, Waver, Belgium). They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli. While the session is running, HCPs can see what is projected into the VRH headset on their Sedakit's X2 controller (i.e. the tablet connected to the glasses).
Midazolam sedationDrug
During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.
| Study group | Role | What they receive |
|---|---|---|
| Control Group | Active comparator | During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.
Patients randomized to the control group will undergo perioperative anesthesia according to the current standards of care, without the addition of the VR headset or headphones. Receives: Drug: Midazolam sedation |
| VRH Group | Experimental | They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli.
During the whole procedure, an anesthesiologist will perform the usual cares, including closely monitoring, and will administrate intravenous sedation (midazolam) when necessary (see sedation protocol in the previous section). Receives: Device: VRH; Drug: Midazolam sedation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Midazolam milligrams
Sedation: Intravenous milligrams of midazolam administered during first 120 minutes of surgery to achieve a RASS (Richmond Agitation-Sedation Scale) of -2 or -3.
Measured: 2 hours
Secondary outcomes (12)
Intensity of postoperative pain
Pain (NRS 0-10)
Measured: 1 hour, 24 hours, 48 hours after surgery and one week later
Anxiety
Anxiety (Numeric Rating Scale 0-10)
Measured: 1 hour, 24 hours, 48 hours after surgery and one week later
Anxiety
Anxiety on State-Trait Anxiety Inventory scale (STAI-6)
Measured: 1 hour, 24 hours, 48 hours after surgery and one week later
Comfort
Comfort during and after surgery (NRS 0-10)
Measured: 1 hour, 24 hours, 48 hours after surgery and one week later
Fatigue
Fatigue (NRS 0-10)
Measured: 1 hour, 24 hours, 48 hours after surgery and one week later
Patient satisfaction
Patient satisfaction (global experience) Likert 1-5
Measured: 5 minutes after surgery
Time perception
Patient's time perception (estimated duration of the surgery, i.e. duration between incision and suture)
Measured: 5 minutes after surgery
Dissociation
Dissociation (NRS 0-10)
Measured: 5 minutes after surgery
Anesthesiologist satisfaction
Anesthesiologist satisfaction (Likert 1-5)
Measured: 5 minutes after surgery
Surgeon satisfaction
Surgeon satisfaction (Likert 1-5)
Measured: 5 minutes after surgery
Nurse satisfaction
Nurse satisfaction (Likert 1-5)
Measured: 5 minutes after surgery
QoR-15F
Score on the quality of recovery, using the QoR-15F
Measured: 1 hour, 24 hours, 48 hours after surgery and one week later
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jan 2023
- Study start15 Feb 2023
- Primary completion3 Aug 2023
- Study completion3 Aug 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Arthroplasty ComplicationsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- prospective, single-center, randomized controlled clinical trial
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Liege
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Michele Carella, University of Liege
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05707234
- Sponsor's protocol ID
- VRH.TKA
- Status last verified
- Mar 2024
- First submitted
- 4 Jan 2023
- Last updated
- 6 Mar 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Carella M, Beck F, Quoilin C, Azongmo MM, Loheac A, Bonhomme VL, Vanhaudenhuyse A. Effect of virtual reality hypnosis on intraoperative sedation needs and functional recovery in knee arthroplasty: a prospective randomized clinical trial. Reg Anesth Pain Med. 2025 May 6;50(5):383-389. doi: 10.1136/rapm-2023-105261.
PubMed 38413184
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Can we Avoid Intravenous Sedation in Patients Undergoing Knee Surgery Under Spinal Anesthesia? A Prospective Randomized Controlled Study Comparing Virtual Reality Hypnosis to Standard of Care
- ClinicalTrials.gov ID
- NCT05707234
- Acronym / sponsor ID
- VRH.TKA
- Conditions
- Arthroplasty Complications, Knee Osteoarthritis, Anesthesia Complication, Hypnotic; Anxiety Disorder, Sedation Complication
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- University of LiegeUniversity, hospital or other
- Study start
- 15 Feb 2023 (actual)
- Primary completion
- 3 Aug 2023 (actual)
- Study completion
- 3 Aug 2023 (actual)
- First posted
- 31 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
For many years, total knee arthroplasty (TKA) has been a common and effective procedure to treat chronic refractory joint pain. Although efforts must be pursued, as general anesthesia remains the main tendency for TKA. Currently, the standard of care to manage procedural anxiety is pharmacological sedation; i.e. the intravenous administration of additional anesthetic agents such as propofol or midazolam. However, pharmacological sedation has considerable undesirable side effects. Hence, risks of intraprocedural adverse events including respiratory depression, hemodynamic perturbations, or paradoxical effects such as hostility, aggression, and psychomotor agitation, are increased. The goal of this prospective, single-center, randomized controlled clinical trial is to systematically evaluate the impact of implementing a protocol of virtual reality hypnosis in patients undergoing total knee arthroplasty under spinal anesthesia.
Detailed description
For many years, total knee arthroplasty (TKA) has been a common and effective procedure to treat chronic refractory joint pain. With a worldwide aging population, as well as a rising rate of obesity and related osteoarthritis, the utilization of TKA has considerably expanded over time, and this increase is expected to continue. Accordingly, healthcare systems are exploring various strategies to address this growing demand, while ensuring efficiency, cost-effectiveness and safety. Among these approaches, and based on several reports comparing the risks and benefits of general and regional anesthesia, a first attempt has been made to switch from performing TKAs under general to spinal anesthesia. Although efforts must be pursued, as general anesthesia remains the main tendency for TKA, results regarding spinal anesthesia are extremely encouraging. As such, spinal anesthesia has been associated with a decreased rate of complications, including wound infection, blood transfusions or mortality, and with reduced length of surgery and hospital stay.
Yet, while spinal anesthesia prevents procedural pain and ensures immobility of the operative territory, the patient is still awake, conscious of all the noises in the operating room, and can have a high level of intraoperative anxiety. Currently, the standard of care to manage procedural anxiety is pharmacological sedation; i.e. the intravenous administration of additional anesthetic agents such as propofol or midazolam. However, pharmacological sedation has considerable undesirable side effects. Hence, risks of intraprocedural adverse events including respiratory depression, hemodynamic perturbations, or paradoxical effects such as hostility, aggression, and psychomotor agitation, are increased. Moreover, it might lead to longer procedure duration or time to discharge, slower recovery, and postoperative delirium or cognitive dysfunction. In addition to these challenges, it becomes clear that procedural sedation directly impacts consumption of drugs such as opioids, triggering the highlighted risk of addiction.
In this context, new international guidelines for risk mitigation in pharmacological sedation have emerged. Both American and European anesthesia societies recommend particular caution in the use of sedative drugs, especially with benzodiazepines and in patients with obesity or obstructive sleep apnea, which are highly comorbid with knee osteoarthritis. However, only providing less, or even no sedatives at all, is not a valuable solution, as it would negatively impact patient comfort and satisfaction and negatively affect clinical workflow. Therefore, alternative, non-pharmacological interventions that would be able to reduce drug requirements and associated risks while ensuring a similar patient experience are being actively sought.
Among those approaches, there is currently a growing interest towards clinical hypnosis, a one-to-one delivered technique inducing "A state of consciousness involving focused attention and reduced peripheral awareness characterized by an enhanced capacity for response to suggestion". The hypnotic state involves the capacities of absorption (tendency to be fully involved in a mental experience), dissociation (a mental separation from the environment), and suggestibility (tendency to comply with hypnotic suggestions). When combined during surgery with conscious IV sedation and local or regional anesthesia, forming the so-called hypnosedation, clinical hypnosis is associated with improved perioperative safety and comfort as well as better clinical outcomes. More precisely, the use of clinical hypnosis during medical procedures has been shown to reduce pain, emotional distress and anxiety while preserving consciousness, spontaneous breathing, reflexes as well as hemodynamic and metabolic changes, to decrease the time spent in the operating room, and to have a beneficial impact on immediate recovery, characterized by reduced fatigue and postoperative nausea and vomiting (PONV). Furthermore, this technique allows to significantly reduce the administrated doses of IV sedation and the associated costs. Yet, several obstacles limit the use of hypnosedation as a standard of care in the operating/ procedure room: the need for continuous patient-side presence of trained professionals in the room (and the cost related to the mobilization of these professionals), the small number of cases per day one healthcare provider can handle, patient's language proficiency, as well as the heterogeneity of the responses to the hypnotic suggestions of patients themselves.
To overcome those limitations, Oncomfort has created Digital Sedation™ sessions, classified as Software as a Medical Device (SaMD), allowing to deliver clinical hypnosis - together with additional integrative therapeutic approaches - through virtual reality, a technique called Virtual Reality Hypnosis (VRH). Virtual reality (VR) is "a computer-generated simulation of a lifelike environment that can be interacted with in a seemingly real or physical way by a person, by means of responsive hardware such as a visor with screen or gloves with sensors. In the medical field, VR has been used as a non-pharmacological mean to alleviate pain, anxiety, and general discomfort during uncomfortable procedures. VR is thought to work by distracting patients from uncomfortable procedures: by giving the illusion of really going into the artificial world, VR is able to capture patient's attention away from the real environment. Accordingly, VR could strengthen the level of absorption and dissociation induced by clinical hypnosis, especially in low hypnotizable persons. Hence, VRH technology allows to deliver clinical hypnosis - and its related benefits- to a considerably greater number of patients. This automated way of delivering hypnosis responds to most of the limitations of the use of clinical hypnosis mentioned supra (e.g. availability of trained staff, language barrier,…).
To date, the Oncomfort's Digital Sedation™ is used in more than 100 hospitals, and more than 80 000 patients have already beneficiated from this type of VRH in daily clinical practice (e.g. interventional radiology, oncology, surgery,…). In line with its intended use, first studies have demonstrated that Digital Sedation™ reduces both experimental and clinical pain, as well as procedural anxiety. In addition, preliminary results indicate that it might replace midazolam during endoscopic urologic surgery, avoiding the respiratory side effects associated with pharmacological sedation. Over the last year, at the CHU of Liège, Digital Sedation™ has been offered to patients during orthopedic surgeries, demonstrating the feasibility of using VRH during TKAs performed under spinal anesthesia. While results seem to be positive in terms of performance of the procedure and patient satisfaction, the potential beneficial impact of this solution has not been systematically addressed yet. The goal of the present study is to objectify those effects, and in particular, to determine whether VRH can replace - at least in part- the intraoperative administration of midazolam, allowing to avoid its associated side effects while ensuring a similar patient's comfort.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- prospective, single-center, randomized controlled clinical trial
| Arm | Type | Receives |
|---|---|---|
| Control Group | Active comparator | Drug: Midazolam sedationDuring the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached. Patients randomized to the control group will undergo perioperative anesthesia according to the current standards of care, without the addition of the VR headset or headphones. |
| VRH Group | Experimental | Device: VRH, Drug: Midazolam sedationThey will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli. During the whole procedure, an anesthesiologist will perform the usual cares, including closely monitoring, and will administrate intravenous sedation (midazolam) when necessary (see sedation protocol in the previous section). |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients >18 yo and scheduled for elective knee arthroplasty under spinal anesthesia
Key exclusion criteria (12 listed)
- Low auditory and/or visual acuity that precludes the use of the device.
- ASA status > 3
- Head or face wounds precluding use of the device.
- Schizophrenia or dissociative disorder.
- Pregnancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VRHThe VR headset and headphones will be placed on patients after the spinal anesthesia, once the patient is positioned and the surgical drapes installed. Patients will then undergo a 120-minute Digital Sedation™ program (Aqua+© 120 Version 1.1 or subsequent version, Oncomfort SA, Waver, Belgium). They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli. While the session is running, HCPs can see what is projected into the VRH headset on their Sedakit's X2 controller (i.e. the tablet connected to the glasses). | Device | VRH Group |
| Midazolam sedationDuring the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached. | Drug | Control Group, VRH Group |
Primary outcome
Midazolam milligrams
Time frame: 2 hours
Sedation: Intravenous milligrams of midazolam administered during first 120 minutes of surgery to achieve a RASS (Richmond Agitation-Sedation Scale) of -2 or -3.
12 secondary outcomes
Intensity of postoperative pain
Time frame: 1 hour, 24 hours, 48 hours after surgery and one week later
Anxiety
Time frame: 1 hour, 24 hours, 48 hours after surgery and one week later
Anxiety
Time frame: 1 hour, 24 hours, 48 hours after surgery and one week later
Comfort
Time frame: 1 hour, 24 hours, 48 hours after surgery and one week later
Fatigue
Time frame: 1 hour, 24 hours, 48 hours after surgery and one week later
Patient satisfaction
Time frame: 5 minutes after surgery
Time perception
Time frame: 5 minutes after surgery
Dissociation
Time frame: 5 minutes after surgery
Anesthesiologist satisfaction
Time frame: 5 minutes after surgery
Surgeon satisfaction
Time frame: 5 minutes after surgery
Nurse satisfaction
Time frame: 5 minutes after surgery
QoR-15F
Time frame: 1 hour, 24 hours, 48 hours after surgery and one week later
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2024.
- Derived from this study: PubMed 38413184Carella M, Beck F, Quoilin C, Azongmo MM, Loheac A, Bonhomme VL, Vanhaudenhuyse A. Effect of virtual reality hypnosis on intraoperative sedation needs and functional recovery in knee arthroplasty: a prospective randomized clinical trial. Reg Anesth Pain Med. 2025 May 6;50(5):383-389. doi: 10.1136/rapm-2023-105261.
- Individual participant dataSharing planned: No
Related trials for Arthroplasty Complications
Not yet recruiting
Lumbar Erector Spinae Plane Block Versus PENG Block for Hip Fracture Surgery
Femur Neck Fracture, Hip Fractures
Not yet recruiting
Negative Pressure Wound Therapy Devices in Total Knee Arthroplasty
Wound Surgical, Diabetes
Not yet recruiting
Comparison of Ultrasound-Guided Erector Spinae Plane Block and Quadro-Iliac Plane Block in Elective Primary Unilateral Total Hip Arthroplasty
Postoperative Pain, Hip Arthroplasty, Total
Recruiting
Radiofrequency Ablation for the Treatment of Post-knee Arthroplasty Chronic Pain.
Chronic Post-surgical Pain, Chronic Post Operative Pain
Not yet recruiting
Opioid Reduction and Enhanced Recovery in Orthopaedic Surgery (OREOS)-Knee
Knee Arthroplasty, Total, Partial Knee Arthroplasty
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing VRH and Midazolam sedation in people with Arthroplasty Complications and Knee Osteoarthritis, run by University of Liege at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Midazolam milligrams (time frame: 2 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05707234, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2024.